Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial

Overview of attention for article published in Frontiers in Cardiovascular Medicine, October 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 1 X post from an account with 2,794 followers.

New Research: Shexiang Baoxin Pill reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial: Background A previous phase IV trial revealed sex… https://t.co/ZZpAL

28 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.